CSIMarket



Quidelortho Corp  (QDEL)
Other Ticker:  
 
 

QDEL's Revenue Growth by Quarter and Year

Quidelortho's Revenue results by quarter and year




QDEL Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter January - 636.87 809.20 152.18
III Quarter October - 509.74 476.06 126.49
II Quarter July 613.40 176.61 201.75 108.25
I Quarter April 1,002.26 375.34 174.65 147.97
FY   1,615.66 1,698.56 1,661.66 534.89



QDEL Revenue second quarter 2022 Y/Y Growth Comment
Quidelortho Corp achieved in the second quarter 2022, above Company average Revenue surge of 247.32% year on year, to $ 613.40 millions.

Looking into second quarter 2022 results within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue growth. While Quidelortho Corp' s Revenue doubling of 247.32% ranks overall at the positon no. 429 in the second quarter 2022.




QDEL Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter January - -21.3 % 431.74 % 14.77 %
III Quarter October - 7.07 % 276.36 % 7.74 %
II Quarter July 247.32 % -12.46 % 86.37 % 4.93 %
I Quarter April 167.03 % 114.91 % 18.03 % -12.52 %
FY   - 2.22 % 210.65 % 2.41 %

Financial Statements
Quidelortho's second quarter 2022 Revenue $ 613.40 millions QDEL's Income Statement
Quidelortho's second quarter 2021 Revenue $ 176.61 millions Quarterly QDEL's Income Statement
New: More QDEL's historic Revenue Growth >>


QDEL Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter January - 24.94 % 69.98 % 20.31 %
III Quarter October - 188.62 % 135.97 % 16.85 %
II Quarter July -38.8 % -52.95 % 15.52 % -26.84 %
I Quarter April 57.37 % -53.62 % 14.77 % 11.6 %
FY (Year on Year)   - 2.22 % 210.65 % 2.41 %




Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #97
Overall #429

Revenue Y/Y Growth Statistics
High Average Low
65.4 % 9.24 % -16.13 %
(Dec 31 2020)   (June 30. 2014)
Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #97
Overall #429
Revenue Y/Y Growth Statistics
High Average Low
65.4 % 9.24 % -16.13 %
(Dec 31 2020)   (June 30. 2014)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Quidelortho's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
188.62 % 18.83 % -53.62 %
(Sep 30 2021)  


QDEL's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2022 Quidelortho Corp disclosed fall in Revenue sequentially by -38.8% to $ 613.40 millions, from $ 1,002.26 millions declared in the previous reporting period.

If you evaluate recent slump in the II. Quarter 2022, you suppose to presume, that usually II. Quarter performance occur softer relative to the quarter before, Catherine Edwards, market contributor from Toronto said.

Within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Quidelortho's Revenue growth quarter on quarter, overall rank is 3669.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #580
Overall #3669
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #580
Overall #3669
Revenue Q/Q Growth Statistics
High Average Low
188.62 % 18.83 % -53.62 %
(Sep 30 2021)  


QDEL's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2022 Quidelortho Corp reported fall in Revenue sequentially by -38.8% to $ 613.40 millions, from $ 1,002.26 millions declared in the previous reporting period.

It's not important problem, as II. Quarter Revenue generally seem to dip in the II. Quarter Catherine Edwards, market contributor from Toronto told.

Within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Quidelortho's Revenue growth quarter on quarter, overall rank is 3669.


Quidelortho's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jul 03 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 2,762.26 $ 2,325.47 $ 1,698.55 $ 1,870.89 $ 1,837.21
Y / Y Revenue Growth (TTM) 50.35 % 24.87 % 2.22 % 86.22 % 180.46 %
Year on Year Revenue Growth Overall Ranking # 642 # 1152 # 810 # 127 # 166
Seqeuential Revenue Change (TTM) 18.78 % 36.91 % -9.21 % 1.83 % -1.35 %
Seq. Revenue Growth (TTM) Overall Ranking # 482 # 144 # 3772 # 2545 # 3396




Cumulative Revenue growth Comment
Quidelortho saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 50.35% year on year, to $ 2,762 millions if the fiscal year would have ended in Jul 03 2022.
Quidelortho's trailing twelve months Revenue growth was higher than company's average 44.09% and higher than 24.87% growth in Mar 31 2022.
But from the previous reporting period rise was beneth at 18.78 % from $2325.47 millions reported in the period from Mar 31 2022 to Jun 30 2021.
Still this was validation of convincing trend, while the average Q/Q TTM growth stands at 9.24%.
The growth is even stronger from twelve months ended Mar 31 2022 clinched at 18.78 % jump from $2325.47 millions in twelve months ending a quarter Mar 31 2022.

In the Healthcare sector 124 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 642, from total ranking in previous quarter at 1152.

Revenue TTM Q/Q Growth Statistics
High Average Low
65.4 %
9.24 %
-16.13 %
(Dec 31 2020)  

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 125
Overall # 642

Revenue TTM Y/Y Growth Statistics
High Average Low
231.63 %
44.09 %
-11.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 104
S&P 500 # 476
Cumulative Revenue growth Comment
Quidelortho saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 50.35% year on year, to $ 2,762 millions if the fiscal year would have ended in Jul 03 2022.
Quidelortho's trailing twelve months Revenue growth was higher than company's average 44.09% and higher than 24.87% growth in Mar 31 2022.
But from the previous reporting period rise was slower at 18.78 % from $2325.47 millions recorded in twelve months ending a quarter before Catherine Edwards added on.
In spite of, this was validation of strength, while the typical Q/Q TTM growth lays at 9.24%.
The momentum was much stronger sequentially showed at 18.78 % increase from $2325.47 millions in twelve months ending a quarter Mar 31 2022.

In the Healthcare sector 124 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 642, from total ranking in previous quarter at 1152.

Revenue TTM Q/Q Growth Statistics
High Average Low
65.4 %
9.24 %
-16.13 %
(Dec 31 2020)  


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 125
Overall # 642

Revenue TTM Y/Y Growth Statistics
High Average Low
231.63 %
44.09 %
-11.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 104
S&P 500 # 476




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
QDEL's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for QDEL's Competitors
Revenue Growth for Quidelortho's Suppliers
Revenue Growth for QDEL's Customers

You may also want to know
QDEL's Annual Growth Rates QDEL's Profitability Ratios QDEL's Asset Turnover Ratio QDEL's Dividend Growth
QDEL's Roe QDEL's Valuation Ratios QDEL's Financial Strength Ratios QDEL's Dividend Payout Ratio
QDEL's Roa QDEL's Inventory Turnover Ratio QDEL's Growth Rates QDEL's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Jul 03 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jul 03 2022


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MSGS's Profile

Stock Price

MSGS's Financials

Business Description

Fundamentals

Charts & Quotes

MSGS's News

Suppliers

MSGS's Competitors

Customers & Markets

Economic Indicators

MSGS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071